Isis hits fifth $1 million milestone payment from GSK in amyloid polyneuropathy clinical trial

16 July 2014

USA-based Isis Pharmaceuticals (Nasdaq: ISIS) announced its latest milestone payment of $1 million from UK pharma major GlaxoSmithKline (LSE: GSK) for the advancement of the Phase II/III study of ISIS-TTRRx in patients with familial amyloid polyneuropathy.

This is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, which is a severe and rare genetic disease, characterized by progressive dysfunction of peripheral nerve and/or heart tissues.

This marks $27 million in upfront and milestone payments for advancing the treatment, and is the fifth of the almost $58 million in milestones Isis is eligible for as the study progresses. Should GSK elect to exercise its option to exclusively license the program, Isis is eligible to receive a license fee, regulatory and sales milestone payments and royalties on sales.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK